🔧

Recovery & Repair

BPC-157 Timeline

30-day subcutaneous tissue repair and gut support protocol. Over 190 preclinical publications demonstrate consistent tissue-repair mechanisms. Timelines reflect animal-model extrapolation combined with practitioner clinical consensus.

Emerging Evidence ~30 Human Subjects

Week 1–2 — Initial Comfort & Gut Calming

Reduced stiffness, digestive relief, and early sleep improvements

Patients commonly report reduced morning stiffness, diminished joint achiness, and early digestive relief within 7–10 days. BPC-157 activates the VEGFR2-Akt-eNOS angiogenesis pathway and upregulates growth hormone receptor expression in fibroblasts. GI mucosal stabilization begins through intestinal permeability support.

📈 Key finding: GH receptor expression increased up to 7-fold within 72 hours in vitro (Chang CH et al., Molecules, 2014).

Week 3–4 — Tissue Repair Accelerates

The "turning a corner" phase for most patients

Range of motion at injury sites improves meaningfully, post-exercise soreness decreases, and gut symptoms become consistently better. Active angiogenesis delivers oxygen and nutrients to repair sites. In rat tendon models, BPC-157-treated tissues show significantly improved biomechanical properties by days 14–21.

Week 6–8 — Structural Remodeling

Load-bearing recovery and inflammation cycle breaks

Tissue begins regaining actual load-bearing capacity. Exercises that felt impossible in week 1 may now feel stable. Mature collagen remodeling replaces initial granulation tissue. Chronic pain patients commonly report the inflammation cycle is "broken."

📄 Human data: 80–100% of interstitial cystitis patients achieved symptom resolution at 6 weeks (Lee E et al., 2024, n=12, open-label).

Week 10–12+ — Integration & Sustained Recovery

Affected areas no longer feel like a "weak link"

For moderate soft-tissue concerns, patients report the affected area integrates fully. GH receptor sensitization may support lasting enhanced responsiveness. Chronic tendon and ligament concerns may require 2–3 complete cycles for full structural support.

⏳ Durability: 87.5% of patients maintained significant comfort improvement at 6–12 months post-treatment (Lee E, Padgett B, 2021, n=16).

⚙️ Protocol Details

Loading: 200–250 mcg SC daily (weeks 1–2), increasing to 300–500 mcg daily (weeks 2–6), then taper to 250 mcg daily or 3–5x/week. Plasma half-life is under 30 minutes, favoring split dosing.

Cycling: 6–8 weeks on, 2–4 weeks off. Effects typically plateau at approximately 6–8 weeks of continuous use.

Variability: Younger patients (<40) typically respond faster due to higher baseline GH levels. Chronic systemic inflammation, poor sleep, and inadequate protein intake may slow response. Exercise enhances blood flow to repair sites.

🏃

Recovery & Repair

TB-500 Timeline

30-day subcutaneous tissue regeneration and athletic recovery protocol. Substantially more human clinical data than BPC-157, with multiple Phase II and Phase III RCTs in ophthalmology and wound healing.

Moderate Evidence Phase II/III Human RCTs

Week 1–2 — Inflammatory Modulation Begins

Mild pain reduction, improved sleep, and increased joint looseness

Thymosin Beta-4 directly targets the NF-κB RelA/p65 subunit, blocking nuclear translocation and suppressing TNF-α-mediated inflammatory signaling. Cell migration activation begins within hours at picogram concentrations. Tβ4 is among the first molecules released by platelets at injury sites.

🔬 Endogenous levels: Wound-fluid concentrations reach ~13 μg/mL (Huff T et al., FASEB Journal, 2002).

Week 3–4 — Angiogenesis & Functional Improvement

Most commonly reported timepoint for "feeling a difference"

Joint mobility improves, workout recovery accelerates, and chronic injury pain reduces noticeably. Tβ4 activates the ILK/Akt survival pathway, a critical kinase cascade that prevents cell death and enhances cell migration and repair.

📄 Phase II RCT: 27% reduction in discomfort and significant corneal staining improvement by days 14–28 (Sosne G, Ousler GW, 2015, n=72).

Week 6–8 — Structural Repair & Collagen Remodeling

Return to higher-intensity exercise, improved skin texture

Significant improvement in chronic tendon and ligament concerns. Collagen deposition matures with decreased scar formation through anti-fibrotic TGF-β pathway signaling. Some patients notice reduced hair shedding as hair follicle stem cell migration activates.

📈 Hair growth: 7 days of Tβ4 treatment doubled the number of active-growth-phase follicles in animal models (Philp D et al., 2004).

Week 10–12+ — Cumulative Remodeling

Resolution of recalcitrant chronic concerns and cardiovascular gains

Enhanced cardiovascular exercise tolerance. Hair regrowth may become visible. In the cardiac pilot RCT, Tβ4-pretreated patients showed 14% improvement in 6-minute walking distance at 6 months (Zhu J et al., 2016, n=10).

⚙️ Protocol Details

Loading: 2.0–2.5 mg per injection, 2–3x/week for 4–6 weeks. Maintenance: 1–2 mg, 1–2x/week.

Cycling: 3 months on, 6 weeks off (or 6 weeks on, 6 weeks off). Hair growth benefits may reverse within 2 weeks of cessation, suggesting continuous or frequent cycling for that goal.

🔗

Combination Stack

BPC-157 + TB-500 Synergy

30-day synergistic recovery stack. BPC-157 operates through localized tissue repair while TB-500 provides systemic anti-inflammatory support. Practitioner consensus suggests timelines accelerate by approximately 25–40% compared to either compound alone.

Emerging Evidence ~25–40% Faster

Week 1–2 — Dual Anti-Inflammatory Cascade

Pain reduction may appear 2–3 days earlier than with either compound alone

Both anti-inflammatory cascades activate simultaneously. Sleep quality improvements are commonly reported. TB-500's NF-κB suppression creates a favorable environment for BPC-157's angiogenic signaling to initiate without inflammatory interference.

Week 3–4 — Measurable Tissue Repair Acceleration

The "turning point" — improved mobility, reduced swelling

BPC-157's VEGFR2-driven angiogenesis builds new capillaries while TB-500's actin dynamics enhance cell migration to injury sites. Most patients experience the combination's clearest differentiation from single-compound protocols during this phase.

Week 6–8 — Substantial Structural Recovery

Superior tissue architecture through complementary collagen regulation

BPC-157 promotes collagen formation while TB-500's anti-fibrotic properties help ensure organized (rather than scar) collagen deposition. This complementary regulation may produce qualitatively superior tissue architecture compared to either peptide alone.

Week 10–12+ — Near-Complete Recovery

Continued remodeling approaches completion for moderate concerns

Standard protocol: BPC-157 at 250–500 mcg/day plus TB-500 at 2–5 mg/week. Maximum 90 consecutive days before 30-day washout.

📈

Growth & Performance

Tesamorelin + Ipamorelin Timeline

Ongoing GH secretagogue stack for body composition and metabolic support. Tesamorelin (Egrifta) is FDA-approved with multiple Phase III RCTs (pooled n=816). The GHRH+GHRP synergy mechanism is well-established.

Strong Evidence Phase III RCT · n=816

Week 1–2 — Sleep Transforms First

Deeper, more restorative sleep with vivid dreams within 3–7 days

Improved sleep quality is consistently the first reported change. Approximately 70% of GH pulses during sleep coincide with slow-wave sleep. The dual-receptor mechanism produces synergistic GH release exceeding either agent alone.

📈 IGF-1 response: Increased by 181 μg/L after just 14 days of tesamorelin 2 mg/day (Stanley et al., 2011, n=13).

Week 3–4 — Body Composition Shifts Begin

Decreased bloating, firmer muscle feel, skin hydration improves

IGF-1 reaches a new steady state — in the landmark Falutz trial, IGF-1 increased 81% over treatment (Falutz J et al., NEJM, 2007, n=412). Lipolytic cascades initiate as GH acts directly on adipocytes, preferentially targeting visceral fat.

🔬 Lab check recommended at week 4 — IGF-1 to confirm biological activity. Target 1.5–2x baseline elevation.

Week 6–8 — Measurable Body Composition Changes

Visible abdominal reduction, improved muscle tone, clothes fit differently

Even a 1 cm waist reduction corresponds to more than 8% reduction in visceral adipose tissue per trial data. Truncal muscle density increases across multiple muscle groups. Cognitive performance may also improve — tesamorelin significantly enhanced executive function in a 20-week RCT (Baker LD et al., 2012, n=152).

Week 10–12+ — Clinically Significant Metabolic Transformation

15–20% visceral fat reduction with improved lipid profiles

At 26 weeks, Phase III data demonstrates 15–20% visceral fat reduction, triglycerides down 50 mg/dL, and improved TC:HDL ratio. Critically, insulin sensitivity is preserved — unlike exogenous GH, tesamorelin's pulsatile release maintains insulin-stimulated glucose uptake.

⚙️ Protocol Details

Timing: Administer in the evening on an empty stomach (2+ hours post-meal) to align with natural nocturnal GH pulsing. Carbohydrates and insulin blunt GH release.

Titration: Start tesamorelin 500 mcg + ipamorelin 100 mcg (weeks 1–2), increase to tesamorelin 1 mg + ipamorelin 200 mcg (weeks 3–4), target 1.5–2 mg + 200–300 mcg thereafter.

Important: VAT reduction reverses upon discontinuation — patients switched to placebo regained visceral fat over 26 weeks in clinical trials.

⚡

Metabolic Optimization

MOTS-C Timeline

30-day subcutaneous metabolic optimization and endurance protocol. A mitochondrial-derived peptide that activates AMPK and enhances glucose metabolism, functionally similar to metformin's mechanism.

Emerging Evidence Phase 1a/1b · n=20

Week 1–2 — AMPK Activation & Metabolic Priming

Early improvements in energy and post-exercise recovery

MOTS-C inhibits the folate cycle, elevates endogenous AICAR, and activates AMPK. GLUT4 translocation to muscle cell membranes begins, enhancing insulin-independent glucose uptake. In mice, 2-week daily MOTS-C injection significantly enhanced treadmill performance (Reynolds JC et al., 2021).

Week 3–4 — Metabolic Adaptation & Functional Gains

Improved exercise tolerance, early body composition shifts

In the CB4211 analog trial, 28 days of 25 mg SC daily reduced liver fat with specificity greater than liraglutide. Fasting insulin and HOMA-IR may begin improving.

Week 6–8 — Cumulative Mitochondrial Remodeling

Noticeable endurance gains and visible body composition changes

Citrate synthase activity and mitochondrial content increase. Myostatin suppression supports lean muscle preservation. MOTS-C appears most effective in metabolically challenged individuals — effects may be more modest in those who are already metabolically healthy.

Week 10–12+ — Sustained Metabolic Support

Maintained physical capacity and cardiovascular protection

Intermittent MOTS-C (3x/week) started late in life maintained physical capacity improvements in animal models. Endogenous MOTS-C levels decline with age — blood levels in young individuals are 11–21% higher than middle-aged and older individuals.

⚖️

Weight Management

Retatrutide Timeline

Ongoing triple-agonist protocol (GLP-1/GIP/glucagon) for weight management at 2.5 mg and 5.0 mg. The first triple receptor agonist, providing energy expenditure enhancement via the glucagon receptor in addition to appetite regulation.

Strong Evidence Phase 2 NEJM · n=338 Phase 3 · n=445

Week 1–2 — Appetite Quiets; GI Adaptation

Appetite suppression within 1–5 days depending on dose

At 2.5 mg: mild appetite suppression, subtle early satiety, 0.5–1.5% weight change. At 5.0 mg: more pronounced suppression, "food noise" reduces dramatically, 1–2% weight change. The glucagon component begins stimulating hepatic fatty acid oxidation even at low doses. This is the peak GI disruption point — tachyphylaxis develops over subsequent weeks.

Week 3–4 — Weight Trajectory Steepens

Cumulative 2–5% body weight reduction with resolving nausea

At 2.5 mg: cumulative 2–4% reduction, nausea resolving. At 5.0 mg: 3–5% reduction, appetite suppressed ~40–50%. Gastric emptying tachyphylaxis explains why nausea improves even as drug levels increase.

💡 Clinical pearl: Starting at 2.5 mg and escalating to 5.0 mg at week 4 significantly reduces GI burden compared to starting directly at 5.0 mg.

Week 6–8 — Metabolic Transformation Accelerates

6–10% weight loss (5.0 mg) with dramatic liver fat reduction

At 5.0 mg: cumulative 6–10% weight loss; liver fat beginning substantial reduction. 72% of patients with baseline prediabetes showing normoglycemia across all doses. The glucagon receptor component drives energy expenditure beyond appetite suppression alone.

📄 Liver data: At 8 mg, liver fat decreased 81% at 24 weeks (Sanyal et al., Nature Medicine, 2024).

Week 10–12+ — Continuous, Non-Plateauing Weight Loss

Weight loss does not plateau — a distinguishing feature

At 5.0 mg: projecting to 18–21% at 48 weeks. Phase 3 results at 68 weeks: 12 mg achieved 28.7% body weight reduction. Fat mass preferentially decreased over lean mass. Comprehensive metabolic improvement across HbA1c, fasting glucose, triglycerides, LDL, and blood pressure.

🧬

Longevity & Cellular

Epithalon Timeline

10-day protocol administered twice yearly for telomere and longevity support. A 70-patient placebo-controlled trial with 15-year follow-up demonstrated 28% decreased mortality and 2-fold lower cardiovascular mortality.

Moderate Evidence 15-Year Follow-up

Days 1–5 — Pineal Reactivation Begins

Improved sleep onset and vivid dreams by day 2–3

Early melatonin modulation drives sleep quality improvements. hTERT (telomerase catalytic subunit) mRNA upregulation begins — in vitro, epithalon induced 12-fold hTERT expression in treated cells (Al-dulaimi et al., 2025).

Days 6–10 — Cumulative Telomerase Activation

Sleep stabilizes, energy and mood enhance

Epithalon-treated human fibroblasts divided past the 44th passage versus control termination at the 34th — surpassing the Hayflick limit. Melatonin regulation is bidirectional — epithalon normalized both depleted and adequate pineal function.

Weeks 2–4 Post-Administration — Benefits Deepen

Circadian rhythm re-entrainment and continued telomere support

Antioxidant enzyme activity (SOD, glutathione peroxidase) remains elevated. In aged rhesus monkeys, epithalon normalized cortisol circadian rhythms and decreased fasting glucose/insulin levels.

Months 1–6 Post-Administration — Persistent Remodeling

Full expression until next cycle; annual dosing provides 4.1-fold mortality reduction

Telomere length measurement may show measurable increases by 6–8 weeks post-course. Twice-yearly cycling mirrors the Korkushko protocol — annual administration provided 4.1-fold mortality reduction versus one-time treatment in a 266-patient trial.

⚙️ Protocol Details

Dosing: 10 mg SC daily for 10 days, twice yearly (100 mg/year). Evening administration preferred for circadian melatonin alignment.

Optimal bloodwork window: 6–8 weeks after completion of each course.

💫

Hormonal Support

Kisspeptin Timeline

4-week cycle for reproductive hormone signaling and libido support. The most robust human clinical data of any peptide in this portfolio for its specific indication, with studies published in JAMA Network Open and the Journal of Clinical Investigation.

Strong Evidence Multiple Human RCTs

Week 1 — Rapid Hormonal & Brain Activation

LH rises within 30 minutes; brain effects precede hormonal changes

LH can double in males. Testosterone begins rising approximately 90 minutes post-dose. fMRI demonstrated enhanced limbic activity during sexual and bonding stimuli within 75 minutes — before testosterone changes occurred (Comninos AN et al., JCI, 2017, n=29, double-blind crossover RCT).

Week 2 — Building Sustained Response

Progressive libido improvement with proper intermittent dosing

With twice-weekly dosing, sustained LH pulsatility enhancement without desensitization. Baseline testosterone gradually rises. Critical: twice-daily dosing causes complete desensitization by day 14, but twice-weekly dosing maintains sustained response through 8 weeks.

Week 3 — Peak Effect Window

Maximal HPG axis sensitization with strongest combined response

In men with hypoactive sexual desire, kisspeptin increased penile rigidity by up to 56% versus placebo and improved happiness about sex (Mills EG et al., JAMA Network Open, 2023, n=32, RCT). In women with HSDD, kisspeptin modulated sexual brain processing with enhanced hippocampal activity.

Week 4 — Completion & Transition

No "crash" expected — works upstream of GnRH without suppression

Brain processing effects resolve within hours upon cessation; hormonal effects return to baseline within days. However, behavioral and psychological improvements may persist longer. Unlike exogenous testosterone, kisspeptin does not suppress the HPG axis.

🔋

Longevity & Cellular

NAD+ Timeline

1000 mg vial, ongoing cellular energy and cognitive support protocol. Strong evidence for NAD+ biology; moderate evidence from oral precursor trials (NR/NMN); very limited data for subcutaneous NAD+ specifically.

Moderate Evidence SC Route Extrapolated

Week 1–2 — NAD+ Pool Restoration Initiates

Improved energy and mental clarity within days to one week

SC delivery bypasses first-pass metabolism for faster delivery than oral. Sirtuin activation begins as intracellular NAD+ rises. Morning administration recommended — NAD+'s energizing effects may interfere with sleep if given in the evening.

Week 3–4 — Sirtuin & PARP Pathway Optimization

Sustained energy, reduced brain fog, improved sleep quality

SIRT1-mediated deacetylation of PGC-1α initiates mitochondrial biogenesis. PARP1 DNA repair capacity restores without depleting NAD+ for sirtuin function. In the NR long-COVID RCT, NAD+ levels increased 2.6- to 3.1-fold after 5–10 weeks with improvements in fatigue and sleep (Wu CY et al., eClinicalMedicine/Lancet, 2025, n=58).

Week 6–8 — Metabolic & Epigenetic Remodeling

Enhanced insulin sensitivity, reduced inflammatory load

Cumulative sirtuin-mediated epigenetic changes take hold. SIRT6 provides telomere protection and endothelial cell senescence prevention. In the MCI pilot trial, NR produced 139% NAD+ increase and reduced pTau217 (an Alzheimer's biomarker) after 8 weeks.

Week 10–12+ — Sustained Anti-Aging Support

Reduced cellular senescence and ongoing mitochondrial remodeling

NAD+ remained elevated at 20 weeks of continuous supplementation. NAD+ declines approximately 50% every 20 years after age 40 — greater baseline depletion produces more dramatic initial response.

⚙️ Protocol Details

Loading: 100–200 mg SC daily for 7–10 days. Maintenance: 50–100 mg SC 1–3x/week.

Co-supplementation: Trimethylglycine (TMG) 500–1000 mg daily supports methylation capacity. Cycling: 8 weeks on, 2–4 weeks off; or continuous maintenance.

✨

Beauty & Skin

GLOW 50/70 Timeline

30-day skin and collagen support plus recovery blend (GHK-Cu + BPC-157 + TB-500). GHK-Cu modulates 32.1% of human genes at the ≥50% change threshold, including 47 DNA repair genes.

Moderate Evidence GHK-Cu Human Studies

Week 1–2 — Recovery Leads; Skin Begins from Within

Pain reduction dominates early; skin gains subtle hydration and "glow"

BPC-157 and TB-500 drive the early experience with anti-inflammatory and mobility improvements. GHK-Cu gene expression changes are initiating — stimulating fibroblast collagen synthesis and decorin production. Injectable GHK-Cu achieves 10–20x higher tissue bioavailability than topical.

📈 Collagen impact: GHK-Cu increased collagen 9-fold in wound models and decorin production by 302% in skin fibroblasts.

Week 3–4 — First Visible Skin Changes Emerge

Fine lines soften, skin tone improves, wrinkle volume reduces

Injectable GHK-Cu shows results earlier than the 8–12 weeks required for topical formulations. MMP/TIMP regulation simultaneously breaks down damaged proteins while promoting new matrix synthesis. In a randomized double-blind trial, GHK-Cu achieved 31.6% reduction of wrinkle volume versus comparator at 8 weeks.

Week 6–8 — Dual Benefits Converge

Noticeable skin firmness, elasticity improvements, structural recovery

BPC-157's collagen-formation capacity is amplified by GHK-Cu's decorin production — a synergy that may produce qualitatively superior tissue architecture. A 12-week facial cream study (n=71) showed increased skin density, reduced laxity, and improved clarity.

Week 10–12+ — Continued Collagen Remodeling

Significant visible collagen changes; results persist beyond treatment

Skin thickness increases, density improves. GHK-Cu's gene expression changes persist beyond the treatment period, meaning results don't immediately reverse after stopping. Multiple cycles typically produce greater cumulative benefit.

🌿

Gut Health + Beauty

KLOW 80 Timeline

30-day four-peptide blend for skin, gut, and inflammatory balance (GHK-Cu + KPV + BPC-157 + TB-500). KPV adds a dedicated anti-inflammatory layer that creates an earlier response window — particularly in the first 3–14 days.

Emerging Evidence 5–10 Days Faster vs GLOW

Week 1–2 — KPV-Driven Rapid Inflammation Dampening

Symptom improvement within 3–7 days — faster than BPC/TB alone

Gut benefits appear first: reduced bloating, digestive comfort, improved bowel regularity. KPV selectively reduces IL-1β, IL-6, TNF-α while leaving anti-inflammatory IL-10 unchanged. Each peptide's anti-inflammatory mechanism is distinct, creating four converging pathways of support.

🎯 Targeted delivery: KPV enters cells via PepT1 transporter, which is upregulated in inflammatory bowel conditions — meaning delivery is enhanced precisely where inflammation exists.

Week 3–4 — Four Pathways Converge

Substantial gut healing, tissue repair, and first visible skin changes

Dual KPV + BPC-157 gut action (unique to KLOW versus GLOW). Measurable tissue repair from BPC-157/TB-500. Improved barrier function may reduce food sensitivities. KPV's antimicrobial activity adds a microbiome-supportive dimension.

Week 6–8 — Full Multi-System Support

Anti-inflammatory platform established, structural recovery, skin firmness

Advanced mucosal healing and sustained gut barrier integrity. Noticeable skin firmness and elasticity improvements. KLOW provides approximately 5–10 days faster initial response than GLOW, with particularly superior outcomes for patients with concurrent gut inflammation.

Week 10–12+ — Sustained Multi-System Optimization

Cumulative immune modulation, collagen remodeling, gut stabilization

Reduced autoimmune reactivity. Near-complete tissue recovery. Significant collagen remodeling visible. Long-term gut health stabilization. Standard protocol: 30 days on, 14–30 days off. For chronic gut conditions, KPV may be pulsed in 2-week intervals.

Across All Protocols

Cross-Cutting Guidance

🕐

The Three Largest Variability Factors

Age, sleep quality, and baseline inflammation level. Patients under 40 with good sleep and low inflammatory burden consistently reach each milestone 1–2 weeks earlier than patients over 55 with disrupted sleep and chronic inflammation. Optimizing sleep (7–9 hours) meaningfully accelerates outcomes across every compound.

🔄

Cumulative Protocols Outperform Single Cycles

For BPC-157, TB-500, GHK-Cu, epithalon, and NAD+, multiple cycles produce progressively greater benefit. Epithalon demonstrates this most dramatically — annual dosing showed 4.1-fold mortality reduction versus one-time treatment.

📊

Evidence Quality Varies Dramatically

Tesamorelin has Phase III RCT data from 816 patients; BPC-157 has no controlled human trials. We transparently communicate these differences because sophisticated patients verify claims independently — and because it's the right thing to do.

⚖️

Our Language Reflects the Evidence

All timelines use structure/function language: "supports," "promotes," "may help," and "patients commonly report." Where evidence is strong, we say so. Where it's emerging, we say that too. This transparency positions Genesis Health as a credible authority in a market where overclaiming is the norm.

Transparency

Evidence Quality at a Glance

We believe you deserve to know the strength of the science behind every protocol we prescribe. Individual results vary.

Protocol	Evidence Level	Key Data Point
Tesamorelin + Ipamorelin	Strong	Phase III RCTs, n=816 pooled
Retatrutide	Strong	Phase 2 NEJM, n=338 + Phase 3
Kisspeptin	Strong	Multiple RCTs, JAMA Network Open
TB-500	Moderate	Phase II/III human RCTs (ocular/dermal)
Epithalon	Moderate	70-patient trial, 15-year follow-up
NAD+	Moderate	Strong biology; SC route extrapolated
GLOW 50/70	Moderate	GHK-Cu human topical studies
BPC-157	Emerging	190+ preclinical; ~30 human subjects
BPC + TB Combo	Emerging	No combination studies; mechanism-based
MOTS-C	Emerging	Phase 1a/1b analog, n=20
KLOW 80	Emerging	No combination or KPV human trials

The information provided on this page is for educational purposes only and is not intended as medical advice. All peptide protocols require physician evaluation and comprehensive laboratory testing before initiation. Timelines represent ranges based on published research and clinical observation; individual results vary based on age, baseline health, and compliance. Statements about peptide therapy have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. Genesis Health NYC · 425 Madison Avenue, New York, NY · (212) 644-9100

What to Expect from Peptide Therapy

Subjective Improvements Precede Lab Changes by 2–6 Weeks

BPC-157 Timeline

⚙️ Protocol Details

TB-500 Timeline

⚙️ Protocol Details

BPC-157 + TB-500 Synergy

Tesamorelin + Ipamorelin Timeline

⚙️ Protocol Details

MOTS-C Timeline

Retatrutide Timeline

Epithalon Timeline

⚙️ Protocol Details

Kisspeptin Timeline

NAD+ Timeline

⚙️ Protocol Details

GLOW 50/70 Timeline

KLOW 80 Timeline

Cross-Cutting Guidance

The Three Largest Variability Factors

Cumulative Protocols Outperform Single Cycles

Evidence Quality Varies Dramatically

Our Language Reflects the Evidence

Evidence Quality at a Glance

Your Personalized Protocol Starts with a Conversation

Ready to Take the Next Step?